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Heat shock proteins (HSPs) of eukaryotes are evolutionarily conserved molecules pres-
ent in all the major intracellular organelles. They mainly function as molecular chaperones 
and participate in maintenance of protein homeostasis in physiological state and under 
stressful conditions. Despite their relative abundance, the large HSPs, i.e., Hsp110 and 
glucose-regulated protein 170 (Grp170), have received less attention compared to other 
conventional HSPs. These proteins are distantly related to the Hsp70 and belong to 
Hsp70 superfamily. Increased sizes of Hsp110 and Grp170, due to the presence of a 
loop structure, result in their exceptional capability in binding to polypeptide substrates 
or non-protein ligands, such as pathogen-associated molecules. These interactions that 
occur in the extracellular environment during tissue injury or microbial infection may lead 
to amplification of an immune response engaging both innate and adaptive immune 
components. Here, we review the current advances in understanding these large HSPs 
as molecular chaperones in proteostasis control and immune modulation as well as 
their therapeutic implications in treatment of cancer and neurodegeneration. Given their 
unique immunoregulatory activities, we also discuss the emerging evidence of their 
potential involvement in inflammatory and immune-related diseases.
Keywords: heat shock protein 110, glucose-regulated protein 170, cytoprotection, innate immunity, antigen cross-
presentation, inflammatory disease
iNTRODUCTiON
Heat shock proteins (HSPs) are constitutively expressed in all living organisms. The HSP nomen-
clature, originated from the observation of their induction by thermal stress, may also be used 
to describe other stress-inducible proteins, such as glucose-regulated proteins or GRPs (1–3). In 
contrast to cytoplasm-resident HSPs, GRPs mainly reside in the endoplasmic reticulum (ER). The 
mammalian HSPs are classified into several families of proteins based on their molecular size. 
Hsp110 and Grp170 are high molecular weight HSPs, which have been less studied compared to 
other conventional HSPs, e.g., Hsp70 and Hsp90 (4, 5). The transcription and subsequent protein 
expression of Hsp110 or Grp170 are stimulated by cytotoxic or proteotoxic stresses, such as heat 
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shock, oxidative stress, chemical agents, hypoxia, viral infections, 
and inflammation. In such situations, these large HSPs work in 
concert with other chaperone molecules (e.g., Hsp70, Grp78) 
to restore protein folding and cellular function to counter pro-
teotoxic stresses and promote cell survival (6–8). This intrinsic 
chaperoning feature of the large HSPs has significant implications 
in several diseases including neurodegeneration and cancer.
Given the superior protein-holding activity of these large 
HSPs and their unique ability to interact with the immune 
system, Hsp110 and Grp170 have been used to induce antigen/
tumor-reactive immune response for cancer eradication (5, 
9, 10). These large HSPs can broadly chaperone antigens for 
presentation to T lymphocytes and amplify inflammatory 
signals in the extracellular environment, suggesting a potential 
endogenous immunostimulatory effects of these large HSPs dur-
ing tissue stress or injury (e.g., microbial infection). Although 
the mechanism of their intracellular or extracellular action still 
needs to be elucidated, emerging evidence indicates that these 
large HSPs may be involved in regulation of an inflammatory 
response and bridging innate and adaptive immunity, which may 
contribute to the pathogenesis of inflammatory and immune-
related diseases. Here, we review the accumulating evidence of 
multifaceted functions of these large HSPs under physiological 
or pathological conditions and discuss the potential applications 
that exploit the distinct activity of the large HSPs to achieve 
therapeutic benefits.
THe LARGe HSPs: DiSTRiBUTiON, 
iNDUCTiON, AND ReGULATiON
Hsp110, also referred to as Hsp105, is one of the major eukaryotic 
HSPs and a member of conservative Hsp70 superfamily (4, 5). 
The studies of Hsp110 have been largely ignored until the cloning 
of its cDNA in the early 1990s (11–13). Hsp110 has been well 
characterized in mammals (i.e., human, mouse, and hamster) (11, 
14–19). There appears to be two forms of Hsp110, 105α, and 105β 
(43 fewer amino acids than 105α) (14). Hsp105α is expressed con-
stitutively in the cytoplasm of cells and can be further induced by 
heat shock and other stressors, whereas Hsp105β, an alternatively 
spliced form of Hsp105α specifically localized in the nucleus, is 
strictly heat-inducible (20). However, the differential roles poten-
tially played by these two versions of Hsp110 remain not well 
studied given their distinct compartmentalization. As one of the 
major HSPs, Hsp110 is easily detectable in most mammalian cell 
lines and tissues (11, 21). Hsp110 is constitutively expressed in the 
various tissues, e.g., brain, liver, ovary, spleen, heart, lung, small 
intestine, and muscles, but most abundant in the brain (13, 14, 
22). Interestingly, mammalian cerebellum expresses little Hsp110 
compared to other brain regions (13). It is not clear if the lack 
of Hsp110 expression contributes to the high sensitivity of the 
cerebellum to heat stroke or alcohol-associated toxicity (23, 24).
Hsp110 along with other HSPs could be induced in a specific 
set of stress conditions including hyperthermia, ethanol, oxida-
tive reagents, recovery from anoxia (i.e., reperfusion injury), 
and inflammation (25, 26). Studies of heat shock factor (HSF) 
knockout mice indicated that the transcription factor HSF1 
is required for induction of Hsp110, Hsp70, and Hsp25/27, by 
thermal stress (27). Exposure of BALB/c mice to fever-range 
whole body hyperthermia (39.5–40°C for 6 h) enhanced Hsp110 
expression in the lung, lymph nodes, and thymus (28). However, 
thermal stress did not appear to influence the Hsp110 levels in the 
rat nervous system (29, 30). Peptide mapping analysis and use of 
various deletion or substitution mutants revealed that Hsp110 is 
phosphorylated at Serine (509) in the β-sheet domain by casein 
kinase II (31). An early study reported that Hsp110 suppressed 
70-kDa heat-shock cognate protein (Hsc70)-mediated protein 
folding, while the phosphorylation of Hsp110 diminished its 
inhibitory activity in  vitro (32). Intriguingly, phosphorylated 
Hsp110 is especially prominent in the brain compared to other 
tissues of mice or rats, suggesting that the phosphorylation of 
Hsp110 may be physiologically significant (33).
Like other HSPs reported to affect the morphologic develop-
ment of cells and organisms (34), Hsp110 is also important for 
reproductive and embryonic development. Fujita and coworkers 
cloned two Hsp110 cognate cDNAs from testis, designated apg-1 
and apg-2 (17, 35, 36). Apg-1 is developmentally expressed in 
human testicular germ cells and sperm, suggesting its potential 
role in spermatogenesis and fertilization (17, 35, 37). Injection 
of antisense oligodeoxynucleotides targeting Hsp110 into the 
rat uterine horn on day 3 of pregnancy substantially reduced 
the number of the implanted embryos (38), implicating a physi-
ological role for Hsp110 in regulation of reproduction. Indeed, 
Hsp110 displayed a differential expression pattern associated 
with the development of palate in mouse embryo (39). A recent 
study showed that Hsp110 plays an essential role in embryonic 
development of mouse hindlimbs (40). Strikingly, the integrity 
of Hsp110 in β-catenin degradation complex is required for Wnt 
signaling pathway, which can lead to embryonic defects upon 
abnormal activation (41, 42).
Grp170, also known as oxygen-regulated protein 150 
(Orp150) or hypoxia-upregulated protein 1 (HYOU1), was first 
described as a 170  kDa molecule inducible by glucose starva-
tion (43). Hypoxia was soon found as a physiological inducer 
of Grp170 (44–48). Cloning and sequence analysis of Grp170 
indicated that Grp170 represented a new stress protein family 
(12). Although they have a somewhat greater degree of sequence 
similarity to the Hsp110 family sequences than to members of 
the Hsp70 family, the Grp170s of mammals are essentially as 
diverged from the Hsp110 family of proteins as they are from the 
Hsp70s (4, 12, 49, 50).
Similar to other ER-resident GRPs (e.g., Grp78, Grp94/gp96), 
Grp170 possesses a C-terminal ER retention sequence, and 
therefore localizes in the ER after protein synthesis. Grp170 is 
inducible by glucose starvation, chronic anoxia/hypoxia, calcium 
depletion, low pH, a variety of reducing conditions, stress-
induced activation of the hypothalamic–pituitary–adrenal (HPA) 
axis, and viral infection that perturb the ER function (44, 51, 52), 
suggesting that Grp170 participates in quality control of protein 
folding in the ER. Grp170 is co-regulated with Grp78 and Grp94/
gp96 by the unfolded protein response (UPR) (53). Transcription 
of these UPR-inducible genes is regulated by ER stress–response 
elements (ERSE) and key transcription factors such as the X-box 
DNA binding protein 1 (XBP-1) and ATF6 (54–57). In addition, 
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Grp170 was also found to localize in the mitochondria and could 
be upregulated by CHOP/GADD153 in response to mitochon-
drial and ER stress (58).
Although HSPs are generally considered to be intracellular 
proteins, they can be mobilized to the plasma membrane or 
released into the extracellular environment (59). HSPs do not 
seem to be secreted from cells via the classical pathway since 
they do not possess a signal peptide. Nonetheless, HSPs may be 
released from cells through either a passive (e.g., cell injury) or 
an active (translocation to the membrane for secretion) process. 
Hightower et al. first reported that rat embryo cells upon heat-
shock rapidly released Hsp70 and Hsp110 (60). The release of 
Hsp110 from human intestinal epithelial cells (IECs) was also 
observed in the physiological process of epithelial renewal, and 
this release was further increased upon pathological cell death 
(61). It was shown that Hsp110 preferentially associated with and 
stabilized misfolded protein in both the ER and cell periphery 
(62), suggesting Hsp110-based chaperoning activity may be 
involved in protein homeostasis at different locations. Recently, 
presence of Hsp110 on the plasma membrane of human B-cell 
non-Hodgkin lymphoma (B-NHL) cell lines was reported to 
correlate to the aggressiveness of lymphoma (63). Interestingly, 
Grp170 was identified on the surface of human sperm, implicating 
its potential physiological role in reproduction and fertilization 
(64). Additionally, Grp170 was found to be released from human 
cancer cells to the circulating system in patients with a range of 
neoplasms (65). Our study showed that both Hsp110 and Grp170 
can gain access to the extracellular space upon cell necrosis and 
exhibit immunoregulatory activity (66). Although the biological 
significance of these surface or extracellular Hsp110 and Grp170 
remain to be determined, these large HSPs are likely to exhibit 
multifaceted effects at cellular sites under physical and pathologi-
cal conditions.
The constitutively expressed Hsc70, also known as HSPA8, 
and stress-inducible Hsp70 are central players in proteostasis 
control, including de novo folding, refolding of stress-denatured 
proteins, oligomeric assembly, protein trafficking, and proteolytic 
degradation (67). It has long been recognized that Hsp110 exists 
in multi-protein complexes containing Hsc70/Hsp70 (68–70) 
and Grp170 associates with other major GRPs (e.g., Grp78, 
Grp94/gp96) in the ER (51, 71), suggesting coordinated activities 
of chaperones in the maintenance of protein homeostasis. Our 
studies demonstrate that Hsp110 and Grp170 are highly effective 
in inhibiting the aggregation of heat-denatured protein substrates 
(50, 68, 72–74). The genetic evidence also came from the observa-
tion that the Hsp110 deficiency impaired the refolding of heat-
denatured luciferase in mammalian cells (75). Not surprisingly, 
Hsp110, Hsp70, and Hsp40 constitute a disaggregase machinery 
with capacity to efficiently disaggregate and refold aggregates of 
chemically or thermally denatured protein (76, 77), further high-
lighting a role of large HSP in molecular chaperoning and protein 
homeostasis. Hsp110 (78–81) and Grp170 (82–84) were recently 
proposed to serve as a nucleotide exchange factor (NEF) for 
Hsc70/Hsp70 and Grp78, respectively, during ATP hydrolysis of 
chaperoning cycle. Given the high efficiency of Hsp110 or Grp170 
in protein holding, and their differential binding preferences for 
peptide residues compared to Hsc70/Hsp70 (85), we believe that 
Hsp110 or Grp170 do not function solely as a co-chaperone or a 
NEF in cellular functions.
LARGe HSP-MeDiATeD 
CYTOPROTeCTiON AND TiSSUe 
HOMeOSTASiS
The intrinsic chaperoning property of large HSPs primarily con-
tributes to their cytoprotective functions under stress conditions. 
Other mechanisms underlying their pro-survival activity may 
involve HSP-mediated suppression of the intracellular apoptotic 
pathways (86). We have demonstrated that both Hsp110 and 
Grp170 are significantly more efficient than Hsc70/Hsp70 in sta-
bilizing and preventing irreversible aggregation of heat-damaged 
protein (50, 68, 72–74), which may be attributed to the large size 
of these two chaperones due to the substantial expansion of their 
C-terminuses (4, 5). The overexpression of Hsp110 in Rat-1 and 
HeLa cells conferred partial thermotolerance and promoted cell 
survival to a severe heat shock (68). Eroglu et al. recently reported 
that Hsp110-deficient mice exhibit more serious brain damage 
and edema in controlled cortical impact model for traumatic 
brain injury (TBI) compared to wild-type counterparts (22). 
Enhancing the expression of the Hsp110 by celastrol treatment 
effectively reduced injury at the impact site (22), suggesting a 
potential benefit of using drugs to induce Hsp110 for reducing the 
pathological effects of TBI. Similarly, Grp170 was highly upregu-
lated in astrocytes undergoing hypoxic stress (47), suggesting 
a cellular protective role of Grp170. Grp170 overexpression in 
cultured neurons increased their resistance to hypoxic/ischemia 
stress, whereas astrocytes with reduced Grp170 expression 
became vulnerable (87). Upregulation of Grp170 also effectively 
ameliorated hepatic ER stress and hypercholesterolemia-related 
liver damage (88).
The accumulation of misfolded or aggregated protein that is 
non-functional and cytotoxic has been implicated in the patho-
genesis of neurodegenerative diseases (89). While it has been 
well established that conventional HSPs (e.g., Hsp70 or Hsp90) 
suppress the neurotoxicity associated with protein misfolding 
both in vitro and in vivo, emerging evidence indicates an essen-
tial neuroprotective effect of large HSPs. Mutant human Cu/Zn 
superoxide dismutase 1 (SOD1) is associated with motor neuron 
toxicity and cell death in an inherited form of amyotrophic lat-
eral sclerosis (ALS; Lou Gehrig disease). Song et al. showed that 
Hsp110 could prevent the aggregation of misfolded SOD1 spe-
cies, resulting in abrogation of the neuron toxicity by rescuing the 
transport defect in transgenic mice and in axoplasm isolated from 
squid giant axons (90). A growing body of evidence suggests that 
soluble alpha-amyloid precursor protein (sAPPalpha), a cleavage 
product of APP, has neurotrophic and neuroprotective properties 
in Alzheimer disease (91). A recent study reported that Grp170 
induced by sAPPalpha is part of this neuroprotective response 
(92). Erogu et al. provided first in vivo genetic evidence support-
ing the role of Hsp110 in pathogenesis of Alzheimer’s disease (93). 
It was shown that Hsp110-deficient mice exhibited accumulation 
of hyperphosphorylated-tau and neurodegeneration. Crossing 
Hsp110-deficient mice with animal strain overexpressing mutant 
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APP resulted in selective appearance of insoluble amyloid β42. 
Analysis of brain tissues from patients with Alzheimer’s disease 
showed the expression of Hsp110 in close proximity to Aβ 
plaques. Together, these results underscore an essential role for 
Hsp110 in maintaining the proper folding environment that is 
required for phosphorylation/dephosphorylation of tau and APP 
processing in vivo.
High expression of HSPs that has been well documented 
in a wide range of human cancer cells supports their crucial 
role in proliferation and survival of tumor cells. Moreover, 
the levels of HSPs have been proposed to be useful prognostic 
biomarkers for tumorigenesis in some cancers (94, 95). Hsp110 
is one of the most highly upregulated proteins in a variety of 
human cancers (96) and can suppress cancer cell apoptosis by 
preventing the release of cytochrome c from the mitochondria 
(97–99). The small interfering RNA-mediated downregulation 
of Hsp110-sensitized human cancer cells to apoptotic induction 
(99). Yu et al. recently provided new insight into the molecular 
mechanism of Hsp110 overexpression in tumorigenesis (41). 
Hsp110 expression was correlated to upregulation of β-catenin 
and transcription of Wnt target genes in many cancers, 
including colorectal cancer and breast cancer. Knockdown of 
Hsp110 disrupted the integration of PP2A into the β-catenin 
degradation complex, resulting in degradation of β-catenin and 
inhibition of proliferation of colon cancer cell lines that harbor 
adenomatous polyposis coli (APC) mutation (41). Given that 
the majority of colon cancer patients have APC mutations and 
active Wnt/β-catenin signaling, these findings establish Hsp110 
as a prognostic biomarker and as a potential therapeutic target 
for the treatment of colon cancer (100, 101).
LARGe HSPs iN iNNATe iMMUNiTY
Several reports have documented the effect of endotoxin free 
large HSPs (i.e., Hsp110 and Grp170) in inducing co-stimulatory 
signals and cytokine responses in innate immune cells, such 
as dendritic cells (DCs) (102, 103). Tumor cells engineered to 
produce a secretable form of Grp170-stimulated DCs to produce 
the pro-inflammatory cytokine TNF-α, which supports the 
extracellular Grp170 as a potential immunostimulatory “danger” 
molecule (104). Additionally, Hsp110 also induced mouse mam-
mary carcinoma cells to elevate expression of IL-6, IL-12, and 
CD40 (102). A similar observation was made in mouse B16F10 
melanoma cells treated with Grp170 (104).
The release of Hsp110 in subsets of human IECs into the intes-
tinal lumen occurred as a consequence of epithelial renewal (61). 
The elevated levels of Hsp110 serve as an immunological “trigger,” 
resulting in expression of CD1d and subsequent activation of 
natural killer T (NKT) lymphocytes (61). We recently demon-
strated that extracellular Grp170 can function as a chaperone for 
microbial DNA, CpG oligodeoxynucleotides (CpG-ODN), which 
facilities immune-mediated recognition and clearance of patho-
gens (66). Grp170 was highly efficient in binding CpG-ODN and 
potentiated the endocytosis of CpG-ODN by macrophages, which 
led to the enhanced activation of toll-like receptor 9 (TLR9) (66). 
It should also be noted that Grp170 is able to directly interact with 
TLR9 and this interaction increases during stimulation of TLR9 
signaling. Furthermore, Grp170–CpG-ODN complex initiated 
innate immunity enhanced the protection of mice from chal-
lenge with Listeria monocytogenes compared to CpG-ODN alone 
(66). This finding uncovered a new feature of extracellular large 
HSPs in modulating the immune sensing of pathogen-associated 
molecular patterns (PAMPs). Together, the active cooperation 
between the extracellular chaperone and TLR9 may be essential 
for amplification of innate immunity and maintenance of the host 
homeostasis.
Exposure of mononuclear phagocytes or macrophages to 
hypoxia-induced upregulation of Grp170 expression, which was 
restricted to foam cells within atherosclerotic lesions (105). The 
biological function of Grp170 in macrophages may be linked 
to the survival or function of this inflammatory cell population 
that is known to contribute to the pathogenesis of atherosclerosis 
(106). Additionally, the expression of Grp170 was highly increased 
in alveolar macrophages and lung epithelial cells in mice upon 
lipopolysaccharide (LPS) challenge (107). Overexpression of the 
Grp170 was able to confer resistance to LPS-induced acute lung 
injury (107). However, the possible role of intracellular Grp170 
in LPS-induced inflammatory response has not been examined. 
Recently, Giffin et al. reported that Grp170 was associated with 
viral interleukin-6 (vIL-6), a cytokine homolog encoded by 
human herpes virus 8 (52). This interaction increased the ability 
of vIL-6 to bind gp130, thereby potentiating vIL-6-induced JAK/
STAT signaling, survival as well as migration of endothelial cells 
(52). This suggests that Grp170 can modulate vIL-6 function 
and promote pro-inflammatory signaling, angiogenesis, and cell 
proliferation.
LARGe HSPs iN ANTiGeN  
CROSS-PReSeNTATiON
In light of exceptional protein-holding capacity and superior 
immunostimulatory activity of the large HSPs (Hsp110, Grp170), 
we have created recombinant heat shock vaccines by complexing 
clinically relevant tumor protein antigens to these large chap-
erones (74, 108–112). These reconstituted complexes exhibited 
potent antitumor activities by eliciting antigen-specific cytotoxic 
lymphocytes (CTL) responses prophylactically and therapeuti-
cally. Due to the nature of these soluble antigen-targeted protein 
vaccines, it is believed that antigens-chaperoned by large HSPs 
are introduced into an antigen cross-presenting pathway in 
professional antigen-presenting cells (APCs), e.g., DCs (9, 113, 
114). Intracellularly processed antigenic peptides are then loaded 
onto major histocompatibility complex (MHC) class I molecules, 
followed by presentation to CD8+ T lymphocytes.
Despite the fact that these large HSPs efficiently facilitate 
a CD8+ T cell response to associated antigens, the mechanism 
underlying large HSP-enhanced antigen cross-presentation 
during interaction with DCs is not completely understood. 
The prolonged existence or stability of antigens is an important 
prerequisite for cross-presentation after internalization because 
antigen degradation by endo/lysosomal proteases can rapidly 
destroy putative antigenic epitopes (115). Hsp110 and Grp170 
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are significantly more efficient than other chaperones in stabiliz-
ing heat-denatured protein substrates (50, 72), which may help 
to protect antigenic epitopes from being degraded. In addition, 
these large HSPs may be able to influence intracellular traffick-
ing of antigens to promote cross-presentation. Kutomi et  al. 
showed that Grp170 shuttled the chaperoned peptide into the 
Rab5+EEA1+ static early endosomes and transferred the peptide 
onto the recycling MHC class I molecules (116).
Using a clinically relevant melanoma protein antigen (i.e., 
gp100), we recently investigated the trafficking pathway of 
Grp170–gp100 vaccine complex internalized (117). We showed 
that the Grp170 directed the antigen gp100 efficiently to the ER 
following uptake into DCs. Grp170-facilitated antigen processing 
and presentation was dependent on the endoplasmic reticulum-
associated protein degradation (ERAD) pathway involving Sec61, 
which targets gp100 for proteasome-mediated degradation in the 
cytosol and subsequent integration into the conventional MHC 
class I restricted antigen-processing pathway. Grp170 can assist 
protein antigen to escape from lysosomal degradation and shuttle 
the antigen into the ER from the early endosomal compartment, 
possibly via a previously reported “ER–endosome fusion” process 
(118–120). Internalized Grp170 may be directly involved in the 
ERAD, because Grp170 in the complex enhanced the interaction 
of gp100 with several molecules known to participate in this path-
way (e.g., Sec61α, VCP/97, CHIP, Grp78). It is conceivable that 
partially unfolded gp100 protein during the vaccine preparation 
serves as an ERAD target once accessing the ER. Since endog-
enous Grp170 also binds to Sec61α, it is possible that internalized 
Grp170 collaborates with other ER chaperones to guide antigen 
retrotranslocation. Interestingly, cytoplasmic chaperone Hsp110 
was recently shown to regulate folding as well as quality control 
of cystic fibrosis transmembrane conductance regulator (CFTR) 
in the ER (62). It is of interest to determine whether endogenous 
Hsp110 is also involved in Grp170-enhanced antigen cross-
presentation by DCs.
It has been established that antigen cross-presentation pro-
moted by HSPs, including Hsp110 and Grp170, requires uptake 
of the HSP–antigen complexes by pattern recognition scavenger 
receptors (SR), such as CD91, LOX1, scavenger receptor A (SRA), 
and SREC (121–127). Although SRA serves as a binding struc-
ture on DCs for exogenous Hsp110 or Grp170, the loss of SRA 
does not seem to significantly alter the overall capacity of DCs 
to process and present Hsp110-associated antigen (i.e., gp100) 
(108, 127, 128). On the contrary, the lack of SRA increased the 
ability of DCs pulsed with large HSP–gp100 complex to stimulate 
gp100-specific naive T cells (108). Given that LOX-1 and SREC 
have been shown to potentiate Hsp70-mediated antigen cross-
presentation (121, 125), we postulate that SRs are functionally 
distinct upon interactions with HSPs that carry antigens (129).
USe OF LARGe HSPs FOR 
DeveLOPMeNT OF CANCeR vACCiNeS
Numerous studies have documented the immunogenicity of 
tumor-derived HSPs, which has been attributed to the indi-
vidually distinct array of antigenic peptides associated with 
these chaperone proteins (130–138). Our early study showed 
that vaccination of mice with Hsp110 or Grp170 purified from 
methylcholanthrene-induced fibrosarcoma resulted in a complete 
regression of the tumor (139). Moreover, tumor-derived Hsp110 
or Grp170 appeared to elicit a more potent antitumor response 
on a molar basis than Hsp70 (139), which may be explained by 
their superior antigen chaperoning capability. Several reports 
suggest that the affinity with which the chaperone binds antigen 
determines its ability to induce a CTL response (140–142). 
Using a more aggressive and less immunogenic mouse B16 
melanoma model, we demonstrated that tumor-derived Grp170 
preparations delayed tumor progression and reduced pulmonary 
metastases (143).
HSP–peptide complexes derived from patient tumors repre-
sent an autologous or personalized vaccine. However, the yield of 
such a vaccine in the clinic is low for certain types of cancer due to 
requirement for patient specimen (144). To overcome this limita-
tion, we developed a recombinant chaperone vaccine by reconsti-
tuting Hsp110/Grp170-tumor protein antigen complexes under 
heat shock conditions (72, 110, 112, 145). A “natural chaperone 
complex” between Hsp110 and the intracellular domain (ICD) of 
human epidermal growth factor receptor 2 protein (HER-2)/neu 
elicited both CD8+ and CD4+ T-cell responses against ICD. The 
Hsp110–ICD complex also significantly enhanced ICD-specific 
antibody responses relative to that seen with ICD alone (112). 
Subsequent studies showed that the Hsp110–ICD complex was 
able to inhibit the development of spontaneous mammary tumors 
in FVB-neu (FVBN202) transgenic mice (145). Consistent with 
this finding, immunization with melanoma antigen gp100 com-
plexed with Hsp110 exhibited therapeutic efficacy against estab-
lished B16 melanoma (72). Strikingly, Hsp110 was more effective 
than complete Freud’s adjuvant in inducing an antitumor immune 
response (72), which is likely to be due to the unique capability 
of the large HSPs in promoting antigen cross-presentation. The 
extensive preclinical studies by us and others have validated this 
recombinant chaperone vaccine approach that uses large HSPs 
to target tumor antigens to professional APCs (74, 108–111, 
146–148), which provide strong scientific rationale for exploiting 
these large HSPs to develop synthetic and non-toxic vaccines for 
cancer immunotherapy.
The similar principle has been used to prepare a recombinant 
vaccine to induce an immune response to infection. McLaughlin 
et  al. showed that recombinant Hsp110 can efficiently bind 
to complete viral antigens and enhance monocyte-stimulated 
proliferation of recall CD4+ T cells in vitro. However, the com-
plexes failed to improve primary immune response in vivo (149). 
Therefore, more studies are necessary to understand immu-
noregulatory activity of the large HSPs in vaccine design directed 
against infectious diseases.
Using colon-26 (CT26) cancer cells stably transfected 
with Hsp110, we showed that Hsp110 overexpression mark-
edly enhanced the immunogenicity of the tumor in  vivo. 
Immunization of mice with irradiated CT26-Hsp110 cells caused 
growth inhibition of unmodified CT26 tumor, associated with 
increased frequency of tumor-specific T cells (150). Similarly, 
engineering of TRAMP-C2 mouse prostate cancer cells to secrete 
Grp170 profoundly enhanced tumor immunogenicity, indicated 
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by increased levels of tumor-infiltrating CD8+ T cells, enhanced 
cytolytic activity, and improved control of distant tumors (104), 
suggesting that the induction or manipulation of large HSPs for 
secretion may help break immune tolerance to cancer cells. We 
also found that the secreted Grp170 chaperoned full length tumor 
protein antigens, which can be potentially captured by DCs in the 
tumor microenvironment (151). Considering abundant tumor 
antigens present in cancer cells, we investigated the feasibility 
of intratumoral delivery of Grp170 using an adenovirus to 
promote antitumor immunity. We showed that the adenovirus 
encoding a secretable form of Grp170 elicited a tumor-reactive 
CTL response (152). Furthermore, this Grp170-expressing 
adenovirus combined with an adenovirus encoding melanoma 
differentiation-associated gene-7/interleukin-24 (mda-7/IL-24), 
a cancer-specific, apoptosis-inducing gene (153), led to a syner-
gistic systemic antitumor effect as shown by improved control of 
both treated and untreated prostate cancers (152).
The significance of pathogen-sensing TLR signaling in 
enhancing antigen presentation by specialized APCs (e.g., DCs) 
and in bridging innate and adaptive immune responses has been 
well established (154). Incorporating pathogen-associated mol-
ecules or TLR agonists into therapeutic vaccines can potentially 
augment immune activation. Recently, we engineered a chimeric 
chaperone by fusing Grp170 with a defined NF-κB-activating 
domain of the TLR5 agonist flagellin. This chimeric molecule, 
termed Flagrp170, combined action of the large HSP in facilitat-
ing antigen cross-presentation and a microbial immunostimula-
tory signal for functional activation of DCs (155). Intratumoral 
administration of an adenovirus expressing Flagrp170 restored 
systemic antitumor immunity against B16 melanoma and distant 
lung metastases compared to either unmodified Grp170 or 
Flagellin. The therapeutic potency of Flagrp170 was also con-
firmed in mouse models of prostate cancer and colon cancer. The 
mechanistic studies showed that Flagrp170-provoked activation 
of tumor-reactive T cells required CD11c+ DCs and CD8+ DCs. 
Although research is needed to better understand the molecular 
and cellular bases of immunoregulation by this chimeric chaper-
one in the immunosuppressive tumor environment, our results 
support the use of this new generation chaperone molecule for 
future design of optimized vaccines to achieve improved treat-
ment outcomes. In a separate study, Chen et  al. reported that 
Grp170-HPV16 E749–57 peptide complex plus the TLR3 agonist 
polyinosinic-polycytidylic acid or poly(I:C), a synthetic analog 
of double-stranded RNA and a molecular pattern associated with 
viral infection, induced synergistically an immune response to 
cervical cancer in mice (156). Therefore, strategic inclusion of a 
microbial component in large HSP-based vaccine regimen will 
further strengthen its immunostimulatory capacity in driving an 
effective CTL response for tumor eradication.
The levels of HSPs, including large HSPs, are generally elevated 
in various human tumors possibly due to the increased require-
ment for chaperone molecules to stabilize the mutated or oncopro-
teins in cancer cells (41, 157). A recent study established a direct 
correlation between Hsp110 expression and lymphoma aggres-
siveness (63). Treatment of human B-NHL cell lines with an anti-
Hsp110 antibody had no direct effect on cell cycle or apoptosis, 
but significantly reduced the tumor burden in xenotransplanted 
immunodeficient mice (63). Hsp110 was reported as a prognostic 
biomarker for the poor survival of patients with breast cancer 
and melanoma (41). Similarly, both the protein and mRNA levels 
of Grp170 were significantly upregulated in several cancer cell 
lines compared to their normal counterparts (158). Induced 
overexpression of Grp170 inhibited the senescence and apoptosis 
of human breast cancer cells, not normal cells (158). Considering 
the potential involvement of these large HSPs in oncogenesis, 
Hsp110 or Grp170 itself may represent a novel tumor-associated 
antigen for immunotargeting. Indeed, vaccination with Hsp110 
cDNA resulted in growth inhibition of colorectal CT26 and 
melanoma B16 tumors, which was associated with stimulation 
of both Hsp110-specific CD4+ and CD8+ T cells (159). Although 
our recombinant chaperone vaccine does not appear to induce 
a significant cellular or humoral response to the Hsp110 (112), 
such a response may be ideal for those cancers with high expres-
sion of the large HSPs.
LARGe HSPs AND iNFLAMMATORY 
DiSeASeS
Inflammatory disease is a term that collectively describes a group 
of apparently unrelated conditions that have common inflam-
matory pathways leading to inflammation, which may result 
in various organ damages (160, 161). Although each of these 
diseases has distinctive epidemiology and pathophysiology, the 
dysregulated inflammatory response is believed to be pivotal to 
the disease pathogenesis. In addition to conventional inflam-
matory disorders, such as inflammatory bowel disease (IBD), 
diabetes, rheumatoid arthritis (RA), and multiple sclerosis (MS), 
some other diseases, such as idiopathic pulmonary fibrosis (IPF), 
myocardial infarction (MI), were recently shown to involve 
inflammatory responses as well. Despite that HSPs have been 
implicated in inflammatory and immune-mediated diseases over 
the past few decades (162–166), the roles of the large HSPs in 
disease pathogenesis, especially in immune-related processes, 
remain less investigated. Understanding of molecular actions of 
Hsp110 and Grp170 in classical inflammatory diseases and those 
that involve an inflammatory process may provide new insights 
into disease mechanisms and lead to new strategies for preven-
tion and therapy of these diseases.
An early study by Colgan et al. showed that Hsp110 released 
from IECs contributes to CD1d surface expression in a novel 
autocrine pathway, suggesting that Hsp110 regulation of CD1d 
represents the “physiologic inflammation” in mucosal tissue 
sites (61). Since CD1d presents self and microbial lipid antigens 
to NKT cells, it is possible that the Hsp110–CD1d axis might 
contribute to the pathogenesis of inflammatory diseases, e.g., 
IBD. Surprisingly, a recent study from this group reported that 
bone-marrow-derived CD1d signals induced NKT cell-mediated 
intestinal inflammation; however, engagement of epithelial 
CD1d elicits protective effects through the STAT3-dependent 
regulation of IL-10, Hsp110, and CD1d itself (167), which high-
lights a role of Hsp110 in IEC-dependent maintenance of gut 
homeostasis. In line with these observations, pharmacological 
stimulation of Hsp110 expression may be exploited to prevent 
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colorectal inflammation and favorably affect the progression 
of IBD. Indeed, human HSP A4 (HspA4, also called Apg2), a 
member of the Hsp110 family, is inducible by chronic inflam-
mation (164, 168). A recent study showed that increased HspA4 
inhibited apoptosis of inflammatory cells, thereby augmenting 
immune response in the gut through the upregulation of Bcl-2 
and IL-17 expression, which led to treatment resistance in IBD 
(164). This result also suggests that HspA4 may be used as a 
potential biomarker for refractory IBD. Interestingly, Zebrafish 
HspA4 was also upregulated in the intestinal epithelium within 
the gut under inflammatory stress conditions (169). Using 
HspA4-deficient mice and human tissue samples, Sakurai et al. 
showed that the expression of HspA4 was inversely correlated to 
gastric ulcer healing induced by endoscopic submucosal resec-
tion (170). Further studies revealed that HspA4 downregulated 
the expression of stromal cell-derived factor 1 (SDF-1, also 
known as CXCL12), which signals through its cognate receptor 
CXC chemokine receptor 4 (CXCR4). The resultant inhibition of 
cell migration delayed gastric ulcer healing (170).
Obesity and associated insulin resistance predispose individu-
als to develop chronic metabolic diseases, such as type 2 diabetes. 
Emerging evidence supports an important role for Grp170 in 
insulin release (171–173) or insulin resistance in diabetes (174, 
175). Kobayashi et al. showed that Grp170 was highly expressed 
on pancreatic beta cells and decrease in serum glucose concen-
tration by fasting strongly suppressed Grp170 expression in the 
pancreas concomitant with decreased insulin level in the serum 
(172). Interestingly, titer of autoantibodies against Grp170 was 
elevated during high-fat diet feeding (171). A significant increase 
in autoantibodies to Grp170 was also observed in patients with 
type I diabetes (176). However, the pathophysiological effect of 
these autoantibodies to Grp170 in diabetes remains unclear.
Involvement of Grp170 in improving insulin sensitivity of 
the skeletal muscle and liver was established in type 2 diabetes 
(175). Overexpression of Grp170 was shown to delay the onset of 
disease and improve insulin sensitivity, subsequently ameliorated 
glucose tolerance in diabetic animals. Conversely, reduction of 
Grp170 in the liver facilitated the disease progress and decreased 
insulin sensitivity (174). Mechanistic studies suggested that the 
improved insulin sensitivity by Grp170 was executed though 
attenuation of oxidative stress and augmentation of insulin 
signaling in the skeletal muscle and liver (174). Recently, Deng 
et  al. showed that Grp170 expression on pancreatic beta cells 
decreased gradually during the pathogenesis of acute necrotizing 
pancreatitis (177). Dekki et al. reported that transthyretin (TTR), 
which promotes insulin release and protects against pancreatic 
beta cell death, was associated directly with Grp78, Grp94, and 
Grp170 in pancreatic beta cells (178). Treatment of beta cells with 
physiological concentrations of TTR triggered a pronounced 
increase in intracellular calcium concentration (179). The TTR-
induced change in calcium levels was abolished when cells were 
treated with an antibody against Grp78 (178). Although Grp170 
was not directly studied in this model, it is likely that Grp170 
along with other chaperone molecules in these multimeric com-
plexes collaboratively regulate the internalization or activity of 
TTR, thereby affecting insulin release. Several studies have shown 
that intracellular Grp170 was involved in regulation of calcium 
signaling or calcium homeostasis (58, 180, 181). However, it 
remains to be determined if such a pathway alters the function 
of pancreatic beta cells and inflammatory processes associated 
with diabetes.
Idiopathic pulmonary fibrosis is a progressive chronic disease 
associated with inflammatory responses, fibrosis, and lung 
dysfunction. Treatment of mice with bleomycin-induced lung 
damage with concurrently enhanced expression of Grp170 in 
the lung (182). Despite a modest exacerbation of inflammatory 
responses in Grp170+/− mice, these animals showed significantly 
ameliorated pulmonary fibrosis, alteration of respiratory dys-
function compared to wild-type counterparts. Although Grp170 
appeared to be a protectant against bleomycin-induced lung 
injury, it promoted lung fibrosis by increasing levels of TGF-β1 
and myofibroblasts (182).
Myocardial infarction (i.e., heart attack) is the irreversible 
myocardial cell damage or death, which occurs during prolonged 
ischemia caused by blockage of a coronary artery. Grp170 
overexpression significantly reduced the hypoxia/reoxygenation-
induced cardiomyocyte death by inhibiting activation of capase-3 
and release of mitochondrial cytochrome C. This protective effect 
of Grp170 also inhibited injury caused by myocardial ischemia–
reperfusion in vivo (181). In addition, increased levels of Grp170 
and Grp170-derived peptide fragments was shown in the plasma 
of patients after MI, which was associated with enhanced ER 
or hypoxic stress and suggested to be prognostic marker that 
predicts a poor outcome (183). Accumulating evidence indicates 
that MI-triggered inflammatory response is involved in injury, 
repair, and remodeling of the infarcted heart (184, 185). Recent 
study showed that stimulation of inflammasomes induced the 
caspase activation associated with maturation and secretion 
of biologically active IL-1β, which can cause additional loss of 
functional myocardium and heart failure in mouse model of MI 
(186). While intracellular Hsp90 has been reported to regulate 
activation of inflammasome (187), the potential effect of intracel-
lular or extracellular Grp170 on inflammasome activity as well as 
in the pathophysiology of MI remain to be examined. Elucidating 
the inflammatory pathways and their contributions to the 
pathogenesis of MI may lead to novel therapies for preventing 
post-infarction heart failure.
Although large HSPs, like other chaperone molecules, 
function to primarily promote and restore cellular or tissue 
homeostasis, they may be involved in immune pathology through 
several mechanisms given their potential immunoregulatory 
effects (Figure  1). Of note, extracellular Grp170 secreted from 
intact cells or released from injured cells facilitate the delivery 
of Grp170–antigen complex to DCs via interaction with surface 
SRs, thereby enhancing the cross-presentation of the HSP-bound 
antigens for T cell activation (9, 113, 114, 117). In addition to 
functioning as “danger” molecules that alert the immune system 
of tissue damage (102, 103), the extracellular Grp170 has a capac-
ity to amplify the inflammatory response triggered by microbial 
signal (66) and possibly endogenous damage-associated molecu-
lar patterns (DAMPs) as well. Indeed, host-derived DAMPs, such 
as RNA (188) and DNA (189, 190), can also be recognized by 
TLRs or other pattern recognition receptors that provokes sterile 
inflammation or inflammatory diseases (191–194). Compared 
FiGURe 1 | The potential role of large HSPs in inflammatory or immune-related diseases. Intracellular HSPs typically function as molecular chaperones to 
promote proteostasis, counteract cellular stresses, and improve cell survival. The extracellular large HSPs, released from the host cells, caused by proteotoxic 
stresses, cell injury, or microbial infection, may be involved in regulation of immune pathways that contribute to immune pathologies. The large HSPs complexed 
with self-antigens can be captured by professional antigen-presenting cells (APCs) through scavenger receptor (SR)-mediated endocytosis. Large HSP-based 
chaperoning enhances the cross-presentation of associated antigens and activation of self-reactive CD8+ T cells. The processing of these HSP–antigen complexes 
may result in activation of CD4+ T cells and production of autoantibodies by B lymphocytes. It is also likely that a cellular or humoral response directed to the large 
HSP itself can be induced in certain pathological conditions. The released large HSPs from injured cells, if complexed with self-DNAs or with microbial DNAs in the 
case of infection, can provoke and amplify inflammation or an innate immune response triggered by toll-like receptors (TLRs) present on sentinel cells, such as 
macrophages (Mφ) or dendritic cells (DCs). Due to the conserved sequence, pathogen-derived microbial HSPs from (e.g., bacteria) may induce an immune 
response that cross-reacts with self HSPs during chronic infection.
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with healthy individuals, serum from patients with autoimmune 
diseases, patients with trauma, and children with septic shock 
shows high concentrations of Hsp70 (59), even though Hsp110 
or Grp170 was not examined in this study.
Cross-recognition of the self and the mycobacterial HSPs by 
T cells suggests that HSPs may act as a link between infection 
and autoimmunity (195). Although the controversy remains, 
the molecular mimicry caused by structural similarity between 
microbial HSPs and mammalian HSPs may lead to autoimmunity 
to self HSPs following bacterial infection (196–198). Consistent 
with this idea, Hsp110 itself can be immunogenic in certain 
contexts, such as DNA vaccination against Hsp110 that resulted 
in priming of T cells reactive with Hsp110 on tumor cells in vivo 
(159). Increased levels of anti-Hsp110 antibodies and enhanced 
expression of Hsp110 have been observed in mice with experi-
mental autoimmune encephalomyelitis (EAE) as well as patients 
with MS (199), which support a potential role of Hsp110 in 
inflammatory autoimmune pathology.
Although therapeutic inhibition of Hsp90 has been evaluated 
in the context of cancer treatment (200), growing evidence indi-
cates that Hsp90 inhibitors also provide benefits for treatment 
of inflammatory disorders. Inhibition of Hsp90 using a small 
molecular inhibitor prevented LPS-induced NF-κB activation 
and nitric oxide production, and attenuated the inflamma-
tory response in EAE (201). Inhibition of Hsp90 reduced the 
activation of the transcription factors STATs and NF-κB by 
pro-inflammatory cytokines in atherosclerotic mice (202). These 
results suggest involvement of Hsp90 and potentially other HSPs 
(e.g., Hsp110, Grp170) in an inflammatory response possibly 
through modulating key regulators of immune signaling path-
ways such as JAK/STATs, TLR4, and NF-κB. We recently showed 
that UPR response enhanced the production of inflammatory 
cytokines (e.g., IFN-β) by DCs stimulated by poly(I:C), which 
involved both TLR3 and melanoma differentiation-associated 
gene-5. This enhanced inflammatory response was associated 
with increased activation of NF-κB and IRF3 signaling as well as 
the splicing of X-box-binding protein-1 (XBP-1), a transcription 
factor known to regulate ER chaperone genes such as Grp170 
(203). It is not clear if the induction of intracellular Grp170 and/
or secretion of Grp170 contribute to UPR-amplified inflamma-
tory response in this context. Moreover, Grp170 is known to 
bind with immunoglobulin in B cells (51) and was suggested 
to functionally compensate for Grp94/Gp96 to facilitate the 
assembly of immunoglobulin (204), implicating a potential role 
of Grp170 in B cell functions. Strikingly, lupus-like autoimmune 
disorder and systemic inflammation are induced in Grp94/Gp96 
TABLe 1 | The activity of large heat shock proteins in multiple diseases.
Pathology Activity Reference
Hsp110 Traumatic brain injury Reduce injury at impact site (22)
Amyotrophic lateral sclerosis Prevent the neuron toxicity mediated by mutant SOD1 protein (90)
Alzheimer’s disease Maintain a proper folding environment for phosphorylation and dephosphorylation of tau and APP processing (93)
Cancer Upregulate β-catenin and transcription of Wnt-targeted genes; suppress cancer cell apoptosis (41, 97)
Inflammatory bowel disease Impair CD1d signal induced NKT cell-mediated intestinal inflammation; enhance treatment resistance by 
upregulating Bcl-2 and IL-17 
(164, 167)
Gastric ulcer healing Delay wound healing by suppressing the expression of stromal cell-derived factor 1 (170)
Multiple sclerosis Increased levels of anti-Hsp110 antibodies (199)
Grp170 Alzheimer’s disease Maintain neuroprotective functions of sAPP alpha (92)
Acute lung injury Protect alveolar cells after LPS exposure (107)
Obesity and diabetes Promote insulin release and enhance the insulin Sensitivity; increased autoantibodies to Grp170 (171, 173–176)
Myocardial infarction Inhibit activation of capase-3 and release of mitochondrial cytochrome C (181)
Idiopathic pulmonary fibrosis Protect against bleomycin-induced lung injury; promote lung fibrosis by elevating levels of TGF-β1 (182)
March 2016 | Volume 7 | Article 759
Zuo et al. Large HSPs in Diseases and Therapy
Frontiers in Immunology | www.frontiersin.org
transgenic mice, in which Grp94/Gp96 was engineered for cell 
surface expression (205). Thus, development of pharmacological 
inhibitors selectively targeting Hsp110 or Grp170 may provide 
new opportunities to treat certain inflammatory or immune-
related diseases (Table 1).
CONCLUSiON
Like other chaperone molecules involve in intracellular protein 
quality control, Hsp110 and Grp170 play essential roles for 
maintaining and restoring protein homeostasis under physi-
ological and stress conditions. The upregulation of these large 
HSPs as part of stress response (e.g., heat shock response, UPR) 
generally provide a cytoprotective effect via assistance with 
protein refolding. Therefore, their manipulation may be strategi-
cally used to slow progress of certain diseases associated with 
protein misfolding or aggregation (e.g., neurodegeneration) or 
treat cancers that highly express Hsp110 or Grp170 to maintain 
oncogenic signaling for sustained proliferation and survivals. 
Due to their superior capacity to hold and target protein antigens 
for DC-mediated cross-presentation, these large HSPs have been 
used to develop antigen-targeted cancer vaccines and to enhance 
the immunogenicity of cancer cells. The efficient generation of an 
antitumor immune response by large HSP-based immunotherapy 
in animal models of several cancers has led to an ongoing phase 
I clinical trial in patients with advanced melanoma. Despite that 
these large HSPs are typically considered to be homeostatic fac-
tors in maintaining cellular function and tissue integrity, it is not 
surprising that they are involved in certain immunopathologies 
(e.g., inflammatory or immune-related diseases) given the well-
documented immunoregulatory activities of surface or extracel-
lular HSPs including the large HSPs at the interface of innate and 
adaptive immunity. A better understanding of multifunctional 
roles of Hsp110 or Grp170, defined by their expression compart-
mentalization as well as the nature, magnitude, or duration of 
stress signals in different contexts, will offer important insight 
into their pathogenic relevancies and assist in the design of new 
potential therapies for treatment of inflammatory disorders (e.g., 
IBD, MS).
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